Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486455 | 0.81 | ALDH1A1 (0.58) | MAPTHTTKMT2AALDH1A1 | |
| SCHEMBL28664343 | 0.81 | CYP4Z1 (0.45) | HTT | |
| SCHEMBL20346363 | 0.80 | SMN1; SMN2 (0.43) | MAPTHTT | |
| SCHEMBL16839695 | 0.78 | LTA4H (0.41) | MAPTHTTKMT2AALDH1A1 | |
| SCHEMBL13516290 | 0.75 | CTNNB1 (0.56) | KMT2AALDH1A1GLA | |
| SCHEMBL28929202 | 0.75 | KDM4E (0.38) | MAPTHTTKMT2APTGDRALDH1A1 | |
| SCHEMBL6484083 | 0.74 | KMT2A (0.62) | MAPTKMT2AALDH1A1 | |
| SCHEMBL6023639 | 0.74 | — | — | |
| SCHEMBL6023129 | 0.73 | BCHE (0.54) | KMT2A | |
| SCHEMBL6482686 | 0.73 | HDAC3 (0.64) | MAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148838-A1 | Novel pyrrolodihydroisoquinolines useful in the treatment of cancer | ALTANA PHARMA AG (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1641794-A1 | NOVEL PYRROLODIHYDROISOQUINOLINES USEFUL IN THE TREATMENT OF CANCER | ALTANA Pharma AG (DE) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005003130-A1 | NOVEL PYRROLODIHYDROISOQUINOLINES USEFUL IN THE TREATMENT OF CANCER | ALTANA PHARMA AG (DE) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148838-A1 | Novel pyrrolodihydroisoquinolines useful in the treatment of cancer | MKI67, BAD, CCAR2 | MAPT 3804/4885HTT 1732/4885KMT2A 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.